CAS 238750-77-1
:Tosedostat
Description:
Tosedostat, with the CAS number 238750-77-1, is a synthetic compound classified as a small molecule inhibitor. It primarily functions as an aminopeptidase N inhibitor, which interferes with the metabolism of amino acids and proteins. Tosedostat has been investigated for its potential therapeutic applications, particularly in the treatment of certain types of cancer, including hematological malignancies. The compound exhibits a mechanism of action that involves the inhibition of protein synthesis, leading to the induction of apoptosis in cancer cells. Tosedostat is typically administered in a clinical setting and has been evaluated in various clinical trials to assess its efficacy and safety profile. Its solubility and stability characteristics are important for formulation and delivery in therapeutic contexts. As with many investigational drugs, ongoing research aims to better understand its pharmacokinetics, optimal dosing regimens, and potential side effects. Overall, Tosedostat represents a promising avenue in cancer treatment, particularly for patients who may not respond to conventional therapies.
Formula:C21H30N2O6
InChI:InChI=1/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1
Synonyms:- alpha-[[(2R)-2-[(1S)-1-Hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]benzeneacetic acid cyclopentyl ester
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
Tosedostat
CAS:Tosedostat (CHR-2797), an oral M1 aminopeptidase inhibitor, turns into CHR-79888, blocks tumor cell proteins, causing cell death.Formula:C21H30N2O6Purity:98.14% - 99.4%Color and Shape:SolidMolecular weight:406.47Tosedostat
CAS:<p>Tosedostat is a potent inhibitor of the enzyme aminopeptidase N. Aminopeptidase N is an enzyme that cleaves peptides at the amino terminus of proteins. Tosedostat inhibits the activity of this enzyme, which leads to autophagy induction and cell death. This drug has been shown to be effective against solid tumours in mice and x-ray crystal structures have been determined for its interactions with hl-60 cells. Tosedostat also displays significant cytotoxicity against k562 cells, a human leukemia cell line, and has been shown to inhibit Jak2 V617F, a tyrosine kinase involved in signalling pathways regulating apoptosis.</p>Formula:C21H30N2O6Purity:Min. 95%Molecular weight:406.47 g/mol






